Cart
sales@molnova.com
Sincalide
CAS No. 25126-32-3
Sincalide( —— )
Catalog No. M29896 CAS No. 25126-32-3
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 120 | In Stock |
|
| 5MG | 222 | In Stock |
|
| 10MG | 357 | In Stock |
|
| 25MG | 587 | In Stock |
|
| 50MG | 822 | In Stock |
|
| 100MG | 1107 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
Biological Information
-
Product NameSincalide
-
NoteResearch use only, not for human use.
-
Brief DescriptionSincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
-
DescriptionSincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number25126-32-3
-
Formula Weight1143.27
-
Molecular FormulaC49H62N10O16S3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 50 mg/mL (43.73 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
NOT Receptor Modulat...
NOT Receptor Modulator 1 is a modulator of nuclear receptor NOT.
-
Myristoylated ADP - ...
Myristoylated ADP - Ribosylation Factor 6, myr - ARF6 (2 - 13)
-
SNAP-25 187-203
This amino acids187 to 203 fragment is derived from the C-terminal helix of synaptosomal-associated protein of 25 kDa (SNAP-25). This peptide is able to rescue exocytosis from botulinum neurotoxin E (BoNT/E)-treated cells, albeit at higher concentrations than the full-length coil.
